ZFHX3 Mutation as a Protective Biomarker for Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Last Updated: Friday, October 22, 2021
The authors found that ZFHX3 mutations are closely related to longer overall survival in NSCLC patients treated with immune checkpoint inhibitors (ICIs), suggesting that ZFHX3 mutations be used as a novel predictive marker in guiding NSCLC ICI treatment.
Advertisement
News & Literature Highlights